Skip to main content

Table 1 Immunovirological response and treatment switch by baseline characteristics

From: Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease

 

n with immunovirological success (%)

immunovirological success: odds ratio (95%CI)

p value

n (%) with treatment switch within 48 months

estimated probability of switch within 48 months (95% CI)

Hazard ratio (95%CI) for switch within 48 months

p value

Gender

       

   males (n: 64, 63%)

41/64 (64)

0.93 (0.40-2.15)

0.860

39/64 (61)

0.67 (0.54-0.80)

1.23 (0.63-2.42)

0.533

   females (n: 38, 37%)

25/38 (66)

  

19/38 (50)

0.56 (0.38-0.74)

  

Age (years)

       

   median (IQR): 44 (37.5-50)

       

   ≥ 50 (n: 27, 26%)

20/27 (74)

1.80 (0.68-4.79)

0.235

19/27 (70)

0.72 (0.54-0.90)

1.73 (0.93-3.22)

0.085

   < 50 (n: 75, 74%)

46/75 (61)

  

39/75 (52)

0.61 (0.48-0.74)

  

Nationality

       

   Italy (n: 83, 81%)

54/83 (65)

1.09 (0.39-3.06)

0.876

50/83 (60)

0.67 (0.56-0.78)

1.61 (0.70-3.69)

0.262

   Other countries (n: 19, 19%)

12/19 (63)

  

8/19 (42)

0.52 (0.25-0.79)

  

Transmission

       

   Heterosexuals (n: 73, 72%)

46/73 (63)

reference category

 

42/73 (57)

0.66 (0.54-0.78)

reference category

 

   men who have sex with men (n: 24, 23%)

17/24 (71)

1.42 (0.52-3.88)

0.487

14/24 (58)

0.73 (0.52-0.94)

0.90 (0.45-1.80)

0.768

   IVDUs/infected blood (n: 5, 5%)

3/5 (60)

0.88 (0.14-5.61)

0.893

2/5 (40)

0.60 (0.16-1.00)

0.57 (0.13-2.55)

0.460

HIV clinical stage

       

   AIDS (n: 43, 42%)

27/43 (63)

0.86 (0.38-1.97)

0.730

22/43 (51)

0.60 (0.43-0.77)

0.76 (0.43-1.34)

0.335

   non-AIDS (n: 59, 58%)

39/59 (66)

  

36/59 (61)

0.68 (0.54-0.82)

  

Hepatitis virus coinfections

       

   Yes (n: 9, 9%) *

5/9 (56)

0.66 (0.16-2.61)

0.550

6/9 (67)

0.72 (0.40-1.00)

1.60 (0.65-3.96)

0.308

   No (n: 93, 91%)

61/93 (66)

  

52/93 (56)

0.63 (0.52-0.74)

  

Baseline CD4+ T cells/μL

       

   median (IQR): 104.5 (48-160)

       

   < 100/μL (n: 48, 47%)

24/48 (50)

3.50 (1.49-8.23)

0.003

27/48 (56)

0.68 (0.52-0.84)

0.97 (0.55-1.70)

0.919

   ≥ 100/μL (n: 54, 53%)

42/54 (78)

  

31/54 (57)

0.61 (0.47-0.75)

  

Baseline HIV-RNA (copies/mL, log 10 )

       

   median (IQR): 5.26 (4.99-5.58)

       

   < 5 log10/mL (n: 26, 25%)

19/26 (73)

0.60 (0.22-1.59)

0.304

12/26 (46)

0.54 (0.32-0.76)

0.88 (0.44-1.76)

0.717

   ≥ 5 log10/mL (n: 76, 75%

47/76 (62)

  

46/76 (60)

0.67 (0.55-0.79)

  

First-line therapy

       

   PIs ** (n: 78, 77%)

49/78 (63)

1.44 (0.53-3.88)

0.474

52/78 (67)

0.75 (0.64-0.86)

4.41 (1.81-10.76)

0.001

   NNRTIs (efavirenz: n: 24, 23%)

17/24 (71)

  

6/24 (25)

0.27 (0.07-0.47)

  
  1. *HBV: 4 (4%); HCV: 3 (3%); HBV+HCV: 2 (2%).
  2. ** Unboosted PIs: 16 (indinavir: 7, nelfinavir: 8, saquinavir: 1); Boosted PIs: 62 (indinavir 2, lopinavir 60)